Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 6, 1996, Pages 1467-1471

  Bender, Andreas R ^a,b   Von Briesen, Hagen ^a   Kreuter, Jörg ^b   Duncan, Ian B ^d   Rubsamen Waigmann, Helga ^a,c  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c BAYER AG   (Germany)

^d ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; NANOPARTICLE; PROTEINASE INHIBITOR; SAQUINAVIR; ZALCITABINE;

ANTIVIRAL ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE FUNCTION; MINIMUM INHIBITORY CONCENTRATION; POLYMERIZATION; PRIORITY JOURNAL; VIRUS INHIBITION;

EID: 0029974417     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.6.1467     Document Type: Article

References (53)

1. Allémann, E., R. Gurny, and E. Doelker. 1993. Drug-loaded nanoparticles - preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 39: 173-191.
2. Beck, P. H., J. Kreuter, W. E. G. Müller, and W. Schatton. 1994. Improved peroral delivery of avarol with polybutylcyanoacrylate nanoparticles Eur. J. Pharm. Biopharm. 40:134-137
3. Bender, A., V. Schäfer, A. M. Steffan, C. Royer, J. Kreuter, H. Rübsamen-Waigmann, and H. von Briesen. 1994. Inhibition of HIV in vitro by antiviral drug targeting using nanoparticles. Res. Virol. 145:215-220.
4. Clerici, M., and G. M. Shearer. 1994. The Th1-Th2 hypothesis of HIV infection new insights. Immunol. Today 15:575-581.
5. Cooney, D. A., M. Dalal, H. Mitsuya, J. B. McMahon, M. Nadkarni, J. Balzarini, S. Broder, and D. G. Johns. 1986. Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem. Pharmacol. 35:1065-2068.
6. Craig, J. C., I. B. Duncan, D. Hockley, C. Grief, N. A. Roberts, and J. S. Mills. 1991. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antivir. Res. 16:295-305.
7. De Clercq, E. 1992. HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retroviruses 8:119-134.
8. Domin, B. A., W. B. Mahony, and T. P. Zimmerman. 1993. Membrane permeation mechanisms of 2′,3′-dideoxynucleosides. Biochem. Pharmacol. 46:725-729.
9. Esser, R., H. von Briesen, W. Brugger, M. Ceska, W. Glienke, S. Müller, A. Rehm, H. Rübsamen-Waigmanil, and R. Andreesen. 1991. Secretory repertoire of HIV-infected human monocytes/macrophages. Pathobiology 59:219-222.
10. Gartner, S., P. Markovits, D. M. Markovitz, M. H. Kaplan, R. C. Gallo, and M. Popovic. 1986. The role of mononuclear phagocytes in HTLV-II/LAV infection. Science 233:215-219.
11. Gendelman, H. E., S. A. Lipton, M. Tardieu, M. I. Bukrinsky, and H. S. L. M. Nottet. 1994. The neuropathogenesis of HIV-1 infection. J. Leukocyte Biol. 56:389-398.
12. Hao, Z., D. A. Cooney, N. R. Hartman, C. F. Perno, A. Fridland, A. L. DeVico, M. G. Sarngadharan, S. Broder, and D. G. Johns. 1988. Factors determining the activity of 2′,3′-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol. Pharmacol 34:431-435.
13. Harvie, P., A. Désormeaux, N. Gagné, M. Tremblay, L. Poulin, D. Beauchamp, and M. G. Bergeron. 1995. Lymphoid tissues targeting of liposome-encapsulated 2′,3′-dideoxyinosine. AIDS 9:701-707.
14. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 373:123-126.
15. Johnston, M. I., and D. F. Hoth. 1993. Present status and future prospects for HIV therapies Science 260:1286-1293.
16. Khoo, S. H., and E. G. Wilkins. 1995. Controversies in anti-retroviral therapy of adults J. Antimicrob. Chemother. 35:245-262.
17. Kitchen, V. S., C. Skinner, K. Ariyoshi, E. A. Lane, I. B. Duncan, J. Burckhardt, H. U. Burger, K. Bragman, A. J. Pinching, and J. N. Weber. 1995. Safety and activity of saqumavir in HIV infection. Lancet 345:952-955.
18. Kreuter, J. 1983. Evaluation of nanoparticles as drug-delivery systems. I. Preparation methods. Pharm. Acta Helv. 58:196-209.
19. Kreuter, J. 1994. Nanoparticles, p. 219-342 In J. Kreuter (ed.), Colloidal drug delivery systems. Marcel Dekker Inc, New York.
20. Kreuter, J., R. N. Alyantdin, D. A. Kharkevich, and A. A. Ivanov. 1995. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674:171-174.
21. 14C-methacrylate) nanoparticle radioactivity after injection in rats and mice J. Pharm. Sci. 68:1443-1447.
22. Kühnel, H., H. von Briesen, U. Dietrich, M. Adamski, D. Mix, L. Biesert, R. Kreutz, A. Immelmann, K. Henco, C. Meichsner, R. Andreesen, H. Gelderblom, and H. Rübsamen-Waigmann. 1989. Molecular cloning of two West African human immunodeficiency virus type 2 isolates that replicate well in macrophages: a Gambian isolate, from a patient with neurologic acquired immunodeficiency syndrome, and a highly divergent Ghanian isolate Proc. Natl. Acad. Sci. USA 86:2383-2387.
23. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734
24. Levy, J. A. 1993. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57:183-289.
25. Martin, J. A. 1992. Recent advances in the design of HIV proteinase inhibitors. Antivir Res 17:265-278.
26. Matsuyama, T., N. Kobayashi, and N. Yamamoto. 1991. Cytokines and HIV infection, is AIDS a tumor necrosis factor disease? AIDS 5:1405-1417.
27. McGann, K. A., R. Collman, D. L. Kolson, F. Gonzalez-Scarano, G. Coukos, C. Coutifaris, J. F. Strauss, and N. Nathanson. 1994. Human immunodeficiency virus type 1 causes productive infection of macrophages m primary placental cell cultures. J. Infect Dis. 169:746-753.
28. Milman, G., and O. Sharma. 1994. Mechanisms of HIVSIV mucosal transmission. AIDS Res. Hum. Retroviruses 10:1305-1312.
29. Mitsuya, H., R. Yarchoan, and S. Broder. 1990. Molecular targets for AIDS therapy Science 249:1533-1544
30. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65: 55-63
31. Nicholson, J. K., G. D. Cross, C. S. Callaway, and J. S. McDougal. 1986. In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). J. Immunol. 137: 323-329.
32. Perno, C. F., S. Aquaro, B. Rosenwirth, E. Balestra, P. Peichl, A. Billich, N. Villani, and R. Calio. 1994. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages J Leukocyte Biol. 56:381-386.
33. Perno, C. F., A, Bergamini, C. D. Pesce, G. Milanese, M. Capozzi, S. Aquaro, S. Thaisrivongs, W. G. Tarpley, G. Zon, C. D'Agostini, G. Rocchi, E. Garaci, and R. Calió. 1993. Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages. J. Infect. Dis 168:1148-1156.
34. Perno, C. F., R. Yarchoan, J. Balzarini, A. Bergamini, G. Milanese, R. Pauwels, E. De Clercq, G. Rocchi, and R. Calio. 1992. Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages. Antivir. Res. 17:289-304.
35. Phillips, N. C., and C. Tsoukas. 1992. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 79:1137-1143.
36. Roberts, N. A., J. A. Martin, D. Kinchington, A. V. Broadhurst, J. C. Craig, I. B. Duncan, S. A. Galpin, B. K. Handa, J. Kay, A. Kröhn, R. W. Lambert, J. H. Merrett, J. S. Mills, K. E. B. Parkes, S. Redshaw, A. J. Ritchie, D. L. Taylor, G. J. Thomas, and P. J. Machin. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361
37. Roberts, N. A., and S. Redshaw. 1993. Discovery and development of the HIV proteinase inhibitor Ro 31-8959, p. 129-151. In J. Adams and V J. Merluzzi (ed.), The search for antiviral drugs Birkhauser, Boston.
38. Robins, T., and J. Plattner. 1993. HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J. Acquired Immune Defic. Syndr. 6: 162-170.
39. Rossi, J. J., D. Elkins, J. A. Zaia, and S. Sullivan. 1992. Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems AIDS Res. Hum. Retroviruses 8:183-189.
40. Rübsamen-Waigmann, H., B. Schröder, L. Biesert, C. D. Bauermeister, H. von Briesen, H. Suhartono, F. Zimmermann, H. D. Brede, A. Regeniter, S. Gerte, E. B. Helm, S. Staszewski, H. Knechten, and U. Dietrich. 1991. Markers for HIV-disease progression in untreated patients and patients receiving AZT: evaluation of viral activity, AZT resistance, serum cholesterol, β2-microglobulin, CD4+ cell counts, and HIV antigen Infection 19:S77-S82
41. Rübsamen-Waigmann, H., W. R. Willems, V. Bertram, and H. von Briesen. 1989. Reversal of HIV phenotype to fulminant replication on macrophages in perinatal transmission. Lancet ii:1155-1156
42. Schäfer, V., J. Kreuter, H. Rübsamen-Waigmann, S. Gerte, and H. von Briesen. 1994. Influence of HIV-infection on the phagocytic activity of monocytes/macrophages and granulocytes. Clin. Diagn. Virol. 1:279-287.
43. Schäfer, V., H. von Briesen, R. Andreesen, A. M. Steffan, C. Royer, S. Tröster, J. Kreuter, and H. Rübsamen-Waigmann. 1992. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages a possibility for antiviral drug targeting. Pharm. Res. 9:541-546.
44. Schafer, V., H. von Briesen, H. Rübsamen-Waigmann, A. M. Steffan, C. Royer, and J. Kreuter. 1994. Phagocytosis and degradation of human serum albumin microspheres and nanoparticles in human macrophages. J. Microencapsulation 11:261-269.
45. Schinazi, R. F., J. R. Mead, and P. M. Feorino. 1992. Insights into HIV chemotherapy AIDS Res Hum Retroviruses 8:963-990.
46. van't-Wout, A. B., N. A. Kootstra, G. A. Mulder-Kampinga, N. Albrecht-van-Lent, H. J. Scherpbier, J. Veenstra, K. Boer, R. A. Coutinho, F. Miedema, and H. Schuitemaker. 1994. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J. Clin. Invest 94:2060-2067.
47. Vella, S. 1994. Update on a proteinase inhibitor. AIDS 8:S25-S29.
48. von Briesen, H., R. Andreesen, R. Esser, W. Brugger, C. Meichsner, K. Becker, and H. RÜbsamen-Waigmann. 1990. Infection of monocytes/macrophages by HIV m vitro Res. Virol. 141:225-231.
49. Waser, P. G., U. Müller, J. Kreuter, S. Berger, K. Munz, E. Kaiser, and B. Pfluger. 1987. Localization of colloidal particles (liposomes, hexylcyanoacrylate nanoparticles and albumin nanoparticles) by histology and autoradiography in mice. Int. J Pharm. 39:213-227.
50. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emmi, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 373:117-122.
51. Weiss, R. A. 1993. How does HIV cause AIDS? Science 260:1273-1279.
52. Winslow, D. L., and M. J. Otto. 1995. HIV protease inhibitors. AIDS 9:S183-S192.
53. Yarchoan, R., J. M. Pluda, C. F. Perno, H. Mitsuya, and S. Broder. 1991. Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. Blood 78:859-884